Domain Associates

Domain Associates is a long-running US life sciences venture firm based in Princeton, with a portfolio history spanning biopharmaceuticals, medical devices, and diagnostics. The firm backs breakthrough platforms across these three sub-verticals rather than narrowing to a single therapeutic area. AI is not the explicit focus; Domain’s thesis is built around clinical assets, device platforms, and diagnostic technologies where the underlying science is the differentiator. For founders building science-led healthcare companies, Domain is a generalist life sciences investor with the longevity to understand long development cycles.

The fund invests at Series A, Series B, and growth stages with check sizes in the $5M to $25M range. That positions Domain to lead or co-lead mid-stage rounds where there is enough technical and clinical data to underwrite further development. The Princeton base puts the team within a short drive of the East Coast pharma corridor.

Founders should approach Domain when their company has clinical or technical proof points — early human data, validated diagnostic performance, or a device with a clear regulatory path. Pre-discovery biotech, services models, and pure software plays are not the typical fit. Because the firm spans three sub-verticals, it is worth tailoring the pitch to the relevant team members rather than treating it as a single homogeneous partnership. Expect thorough scientific diligence and an investor that thinks in milestones tied to regulatory and clinical progress.